HN2006032615A - Derivados de carboxamida como antagonistas del receptor muscarinico - Google Patents

Derivados de carboxamida como antagonistas del receptor muscarinico

Info

Publication number
HN2006032615A
HN2006032615A HN2006032615A HN2006032615A HN2006032615A HN 2006032615 A HN2006032615 A HN 2006032615A HN 2006032615 A HN2006032615 A HN 2006032615A HN 2006032615 A HN2006032615 A HN 2006032615A HN 2006032615 A HN2006032615 A HN 2006032615A
Authority
HN
Honduras
Prior art keywords
antagonists
carboxamide derivatives
muscarinic
receiver
muscarinic receiver
Prior art date
Application number
HN2006032615A
Other languages
English (en)
Inventor
Alan Glossop Paul
John Mantell Simon
Sinclair Strang Ross
Anne Louise Watson Cristine
Wood Anthony
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of HN2006032615A publication Critical patent/HN2006032615A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

LA PRESENTE INVRENCION SE REFIERE A COMPUESTOS, PROCEDIMIENTOS E INTERMEDIOS PARA LA PREPARACION DE, COMPOSICIONES QUE LOS CONTIENEN Y A LOS USOS DE TALES DERIVADOS.
HN2006032615A 2005-09-21 2006-09-21 Derivados de carboxamida como antagonistas del receptor muscarinico HN2006032615A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71946705P 2005-09-21 2005-09-21
US71947705P 2005-09-21 2005-09-21
US71946805P 2005-09-21 2005-09-21

Publications (1)

Publication Number Publication Date
HN2006032615A true HN2006032615A (es) 2010-10-04

Family

ID=37698323

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2006032615A HN2006032615A (es) 2005-09-21 2006-09-21 Derivados de carboxamida como antagonistas del receptor muscarinico

Country Status (43)

Country Link
US (3) US7772223B2 (es)
EP (1) EP1928821B1 (es)
JP (1) JP4221447B1 (es)
KR (1) KR100976909B1 (es)
CN (1) CN101268046B (es)
AP (1) AP1983A (es)
AR (1) AR055171A1 (es)
AT (1) ATE420069T1 (es)
AU (1) AU2006293618B9 (es)
BR (1) BRPI0616111B8 (es)
CA (1) CA2623332C (es)
CR (2) CR9814A (es)
CU (1) CU20100115A7 (es)
CY (1) CY1108880T1 (es)
DE (1) DE602006004768D1 (es)
DK (1) DK1928821T3 (es)
DO (1) DOP2006000202A (es)
EA (1) EA013083B1 (es)
EC (1) ECSP088265A (es)
ES (1) ES2318794T3 (es)
GE (1) GEP20104880B (es)
GT (1) GT200600422A (es)
HK (1) HK1117163A1 (es)
HN (1) HN2006032615A (es)
HR (1) HRP20090127T3 (es)
IL (1) IL189453A (es)
MA (1) MA29839B1 (es)
ME (1) ME01106B (es)
MX (1) MX2008002805A (es)
MY (1) MY143581A (es)
NL (1) NL2000241C2 (es)
NO (1) NO340975B1 (es)
NZ (1) NZ566023A (es)
PE (1) PE20070460A1 (es)
PL (1) PL1928821T3 (es)
PT (1) PT1928821E (es)
RS (2) RS50855B (es)
SI (1) SI1928821T1 (es)
TN (1) TNSN08137A1 (es)
TW (1) TWI322143B (es)
UY (1) UY29798A1 (es)
WO (1) WO2007034325A1 (es)
ZA (1) ZA200801432B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
US20100160279A1 (en) * 2006-09-22 2010-06-24 Pfizer Inc Azetidine Derivatives as Muscarinic Receptor Antagonists
ES2364727T3 (es) * 2007-03-16 2011-09-13 Pfizer Limited Sal clorhidrato de 5-[3-(3-hidroxifenoxi)azetidin-1-il]-5-metil-2,2-difenilhexanamida.
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドPfizer Limited 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
CN103201244B (zh) * 2010-08-26 2015-06-17 阿尔比马尔公司 用于制备1-溴代-2-(环丙基甲氧基)-5-氟代-4-甲氧基苯的方法
CN103242214B (zh) * 2013-05-02 2016-04-06 陕西步长高新制药有限公司 一种吲哚衍生物及其制备方法
KR101538846B1 (ko) * 2013-07-30 2015-07-22 동아에스티 주식회사 신규한 바이페닐 유도체 및 그의 제조방법
WO2018167804A1 (en) 2017-03-15 2018-09-20 Mylan Laboratories Limited Novel polymorphs of (5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide hydrochloride
LT3691620T (lt) 2017-10-05 2022-09-26 Fulcrum Therapeutics, Inc. P38 kinazės inhibitoriai, sumažinantys dux4 ir pasrovinių genų raišką, skirti fshd gydymui
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN111423434A (zh) * 2019-01-09 2020-07-17 四川海思科制药有限公司 一种碳酰胺衍生物及其制备方法
WO2020261160A1 (en) * 2019-06-25 2020-12-30 Mylan Laboratories Limited Methods and intermediates for preparing hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
AU2021296221A1 (en) 2020-06-26 2023-02-02 Mylan Pharma Uk Limited Formulations including 5-(3-(3-hydroxyphenoxy)azetidin-1-yl)-5-methyl-2,2-diphenylhexanamide
WO2023049696A1 (en) * 2021-09-21 2023-03-30 Corteva Agriscience Llc Methylation of 2-chloro-6-fluorophenol

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2886574A (en) 1956-11-19 1959-05-12 Upjohn Co Quaternary ammonium salts of 2, 2-diphenyl-4, 4-dimethyl-4-pyrrolidino-butyramide
US4219559A (en) 1979-01-10 1980-08-26 Janssen Pharmaceutica N.V. N-Heterocyclyl-4-piperidinamines
GB8824262D0 (en) * 1988-10-17 1988-11-23 Pfizer Ltd Therapeutic agents
US5070087A (en) * 1989-05-08 1991-12-03 A. H. Robins Company, Incorporated Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
ATE235903T1 (de) * 1996-12-02 2003-04-15 Kyorin Seiyaku Kk Neue derivate von n-substituierten pyrrolidin derivaten und deren herstellungsverfahren
EP0848964B1 (de) * 1996-12-17 2007-07-25 Filtertek B.V. Rückschlagventil, insbesondere für die Medizintechnik
JPH11100366A (ja) * 1997-09-29 1999-04-13 Kyorin Pharmaceut Co Ltd 新規n−置換環状アミン誘導体及びその製造法
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
BR0215348A (pt) 2001-12-20 2004-11-16 S A L V A T Lab Sa Derivados de carbamato de 1-alquil-1-azoniabiciclo[2-2]octano e uso destes como antagonistas do receptor muscarìnico
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
EP1375508A1 (en) 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
RU2005111589A (ru) 2002-09-17 2006-01-20 Актелион Фармасьютиклз Лтд. (Ch) Производные 1-пиридин-4-илмочевины

Also Published As

Publication number Publication date
TNSN08137A1 (fr) 2009-07-14
BRPI0616111B8 (pt) 2021-05-25
KR20080037103A (ko) 2008-04-29
AP1983A (en) 2009-03-24
NZ566023A (en) 2010-02-26
CR9814A (es) 2008-04-16
US7772223B2 (en) 2010-08-10
RS20080119A (en) 2009-05-06
ATE420069T1 (de) 2009-01-15
SI1928821T1 (sl) 2009-04-30
US20110251164A1 (en) 2011-10-13
ME01106B (me) 2013-03-20
NL2000241C2 (nl) 2009-01-05
IL189453A0 (en) 2008-08-07
WO2007034325A1 (en) 2007-03-29
DE602006004768D1 (de) 2009-02-26
CR20130209A (es) 2013-09-19
BRPI0616111B1 (pt) 2019-10-08
MA29839B1 (fr) 2008-10-03
CU23910B1 (es) 2013-06-29
DOP2006000202A (es) 2007-04-15
EA200800540A1 (ru) 2008-08-29
PL1928821T3 (pl) 2009-06-30
NL2000241A1 (nl) 2007-03-22
RS51680B (en) 2011-10-31
CU20100115A7 (es) 2011-10-14
PE20070460A1 (es) 2007-05-14
NO20081001L (no) 2008-03-25
US8486992B2 (en) 2013-07-16
TW200745024A (en) 2007-12-16
PT1928821E (pt) 2009-03-10
BRPI0616111A2 (pt) 2011-06-07
NO340975B1 (no) 2017-07-31
MX2008002805A (es) 2008-04-07
IL189453A (en) 2014-06-30
GEP20104880B (en) 2010-01-11
ZA200801432B (en) 2009-07-29
GT200600422A (es) 2007-05-28
HK1117163A1 (en) 2009-01-09
ES2318794T3 (es) 2009-05-01
EP1928821B1 (en) 2009-01-07
CN101268046A (zh) 2008-09-17
EA013083B1 (ru) 2010-02-26
EP1928821A1 (en) 2008-06-11
JP4221447B1 (ja) 2009-02-12
UY29798A1 (es) 2007-04-30
CY1108880T1 (el) 2014-07-02
AU2006293618B9 (en) 2009-10-29
AR055171A1 (es) 2007-08-08
AU2006293618A1 (en) 2007-03-29
MY143581A (en) 2011-05-31
US8268881B2 (en) 2012-09-18
ECSP088265A (es) 2008-04-28
RS50855B (sr) 2010-08-31
CN101268046B (zh) 2012-07-25
CA2623332C (en) 2012-05-01
US20100029720A1 (en) 2010-02-04
HRP20090127T3 (en) 2009-06-30
CA2623332A1 (en) 2007-03-29
DK1928821T3 (da) 2009-03-16
AU2006293618B2 (en) 2009-10-08
JP2009508933A (ja) 2009-03-05
US20070105831A1 (en) 2007-05-10
TWI322143B (en) 2010-03-21
KR100976909B1 (ko) 2010-08-18

Similar Documents

Publication Publication Date Title
HN2006032615A (es) Derivados de carboxamida como antagonistas del receptor muscarinico
HN2008000178A (es) Compuestos triciclicos, composiciones y procedimientos
CR10922A (es) Derivados de indol como antagonistas receptores de s1p1
ECSP11011517A (es) Compuestos antivirales
CR9589A (es) Agonistas del receptor de niacina, composiciones que contienen tales compuestos y procedimientos para tratamiento
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
GT200600255A (es) Antagonistas y agonistas de piperazin-piperidina del receptor 5-ht1a
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
HN2011002272A (es) Derivados de indol como antagonistas del receptor crth2
HN2010001563A (es) Compuestos
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
BRPI0809579A8 (pt) formas cristalinas e seus usos
SV2005002061A (es) Derivados de piridilo y su uso como antagonistas del receptor mglu5 ref. x-16538
BRPI0820043A8 (pt) Atividades do receptor de vitamina d e seus usos
SV2009003429A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
ECSP11010753A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
HN2009003357A (es) Nuevos compuesto ligandos del receptor de la adenosina a3
DOP2006000124A (es) Potenciadores del receptor ampa
CR9595A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona
PA8795901A1 (es) Compuestos novedosos activos como antagonistas de receptores muscarinicos
CU23564A3 (es) Derivados de carboxamida como antagonistas del receptor muscarínico
CU20110003A7 (es) Compuestos novedosos activos como antagonistas de receptor muscarínico